The Optimized Lipid-Modified Prodrug for CNV Treatment.
Lv X, Shen J, Du X, Yue B, Zhang Q, Chang W, Miao Y, Ji Z, Chen L, Gong Y, Yang Y, Chen Q.
Lv X, et al. Among authors: zhang q.
Adv Mater. 2025 Feb 2:e2419263. doi: 10.1002/adma.202419263. Online ahead of print.
Adv Mater. 2025.
PMID: 39895155